Advertisement
Canada markets closed
  • S&P/TSX

    22,690.39
    -36.37 (-0.16%)
     
  • S&P 500

    5,505.00
    -39.59 (-0.71%)
     
  • DOW

    40,287.53
    -377.49 (-0.93%)
     
  • CAD/USD

    0.7282
    -0.0016 (-0.22%)
     
  • CRUDE OIL

    80.25
    -2.57 (-3.10%)
     
  • Bitcoin CAD

    91,715.46
    +3,724.34 (+4.23%)
     
  • CMC Crypto 200

    1,379.92
    +49.03 (+3.68%)
     
  • GOLD FUTURES

    2,402.80
    -53.60 (-2.18%)
     
  • RUSSELL 2000

    2,184.35
    -13.94 (-0.63%)
     
  • 10-Yr Bond

    4.2390
    +0.0500 (+1.19%)
     
  • NASDAQ

    17,726.94
    -144.28 (-0.81%)
     
  • VOLATILITY

    16.52
    +0.59 (+3.70%)
     
  • FTSE

    8,155.72
    -49.17 (-0.60%)
     
  • NIKKEI 225

    40,063.79
    -62.56 (-0.16%)
     
  • CAD/EUR

    0.6690
    -0.0003 (-0.04%)
     

NeuroOne® to Present at the Sidoti Micro-Cap Virtual Conference on May 10

NeuroOne Medical Technologies Corp
NeuroOne Medical Technologies Corp

EDEN PRAIRIE, Minn., May 05, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that CFO Ron McClurg will present at the Sidoti Micro-Cap Virtual Conference being held May 10-11, 2023.

Presentation date:

Wednesday, May 10, 2023

Presentation time:

10:45 a.m.*

Registration:

sidoti.com/events

Live presentation:

Session link

1x1 meetings:

Investors may request meetings by contacting their Sidoti representative or NeuroOne Investor Relations.

 

 

*Please note that the presentation date and time are subject to change. Attendees may refer to the program agenda for more information.

ADVERTISEMENT

About NeuroOne

NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit nmtc1.com.

*Caution: Federal law restricts this device to sale by or on the order of a physician.

Contact:
800-631-4030
ir@nmtc1.com